Appeal No. 2006-1036
Application No. 10/191,760
6. A method to obtain therapeutic levels of Factor VIII in a
mammal comprising:
administering less than 1010 infectious units of a
recombinant high capacity adenoviral vector per kg of body
weight or less than 1012 viral particles of the recombinant high
capacity adenoviral vector per kg of body weight intravenously
to the mammal’s liver;
wherein the recombinant high capacity adenoviral vector
comprises:
an Ad5 left terminus;
a human or canine Factor VIII cDNA under the control of a
liver specific promoter, wherein the B-domain of the Factor
VIII cDNA has been deleted; and
an Ad5 right terminus.
13. A method of treating hemophilia A in a mammal,
comprising:
administering less than 1010 infectious units of a
recombinant high capacity adenoviral vector per kg of body
weight or less than 1012 viral particles of the recombinant high
capacity viral vector per kg of body weight intravenously to the
mammal’s liver, said recombinant high capacity adenoviral
vector comprising:
an Ad5 left terminus;
a human or canine Factor VIII cDNA under the control of a
liver specific promoter, wherein the B-domain of the
Factor VIII cDNA has been deleted; and
an Ad5 right terminus;
thus generating therapeutic amounts of Factor VIII in
said mammal to substantially ameliorate the effects of
hemophilia A.
Claims 6, 12, 13, and 17 stand rejected under 35 U.S.C. § 112, first
paragraph, on the grounds that the specification fails to enable the full scope
of the claimed subject matter. We reverse.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: September 9, 2013